Qiu Dong, Zhang Xiao-Hui, Wang Yang, Chen Cheng
Department of Respiratory and Critical Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China.
Front Oncol. 2024 Sep 20;14:1404173. doi: 10.3389/fonc.2024.1404173. eCollection 2024.
RET fusions were discovered in non-small cell lung cancer (NSCLC), and the efficacy of RET-targeted treatment in these patients has been previously established. However, patients with required resistance to RET-TKIs have limited treatment options. Herein, we describe a case of critical and advanced lung adenocarcinoma harboring RET fusion. Despite a significant response to Prasetinib previously, the patient developed refractory malignant pleural effusion after 24 months of treatment. He was treated simultaneously with intrapleural plus systemic Tislelizumab injection combined chemotherapy, thereby achieving an excellent clinical benefit maintaining control of pleural effusion for over 6 months. Hence, we would like to discuss intrapleural immunotherapy as an additional treatment method in refractory malignant pleural effusion while demonstrating good treatment tolerance.
在非小细胞肺癌（NSCLC）中发现了RET融合，并且先前已经确定了RET靶向治疗在这些患者中的疗效。然而，对RET-TKIs产生耐药性的患者治疗选择有限。在此，我们描述了一例患有RET融合的晚期肺腺癌病例。尽管患者先前对普拉替尼有显著反应，但在治疗24个月后出现了难治性恶性胸腔积液。他接受了胸腔内联合全身注射替雷利珠单抗联合化疗，从而获得了良好的临床疗效，胸腔积液得到控制超过6个月。因此，我们想讨论胸腔内免疫疗法作为难治性恶性胸腔积液的一种额外治疗方法，同时证明其具有良好的治疗耐受性。
